Citation

Wollweber B, Keck ME, Schmidt U. Ther. Adv. Psychopharmacol. 2015; 5(4): 208-213.

Affiliation

Max Planck Institute of Psychiatry, Clinical Department, Head of Trauma Outpatient Clinic and RG Molecular Psychotraumatology and Closed Ward, Kraepelinstrasse 10, 80804 Munich, Germany.

Copyright

(Copyright © 2015, SAGE Publishing)

DOI

10.1177/2045125315585652

PMID

26301076

PMCID

PMC4535046

Abstract

INTRODUCTION: There is no drug treatment for nonsuicidal self-injury (NSSI), a highly prevalent and burdensome symptom of several psychiatric diseases like posttraumatic stress disorder (PTSD), personality disorders, and major depression (MD).

METHODS: Here, we present a retrospective series of three patients demonstrating a persistent remission in MD-associated NSSI in response to treatment with antipsychotics possessing marked D1 receptor antagonistic activity.

RESULTS: To the best of the authors' knowledge, the case series presented is only the second clinical paper suggesting a role for D1 antagonists in NSSI drug therapy.

CONCLUSIONS: Together with previously published data from rodent models, the findings suggest a role for D1 antagonists in NSSI drug therapy and hence for the D1 receptor in NSSI pathogenesis. This conclusion is limited by the facts that the patients presented here received polypharmacy and that the D1 receptor antagonistic antipsychotics suggested here as effective 'anti-auto-aggressants' do not address D1 receptors only but multiple neurotransmitter receptors/systems.

Language: en